What is Dasatinib ?

Dasatinib is an oral tyrosine kinase inhibitor primarily used in the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive. It functions by blocking the activity of the BCR-ABL protein and other kinases involved in cancer cell proliferation, thereby helping to halt the growth and spread of malignant cells. By targeting specific cellular pathways, Dasatinib offers a focused approach in the management of these hematological malignancies.

• Diarrhea
• Headache
• Nausea
• Fatigue
• Skin rash
• Muscle pain
• Swelling of hands or feet
• Infection
• Bleeding

• May cause fluid retention leading to swelling and shortness of breath.
• Risk of bleeding; use caution in patients with a history of bleeding disorders.
• Increased risk of infections; monitor for signs and symptoms.
• Potential for pulmonary arterial hypertension; monitor for respiratory symptoms.
• Use with caution in patients with pre-existing liver disease as it may cause hepatotoxicity.
• Avoid use in patients with severe cardiac issues.
• May interact with other medications; evaluate all concurrent medications.
• Pregnant women should avoid handling the medication due to potential harm to the fetus.